Study Name:
Depemokimab as an extended treatment duration biologic in adults with COPD and type 2 inflammation
Targeted Disease(s):
COPD
Purpose of Study:
The purpose of the study is to determine the safety and tolerability of the study drug in patients with uncontrolled moderate to severe COPD. Join a COPD Study Evaluating a Long-Acting, Twice-Yearly Injection We’re currently enrolling participants in a clinical study evaluating an investigational therapy for COPD. If you’re experiencing COPD flare-ups despite regular use of your maintenance inhaler, you may qualify. You may be eligible if you:
- Are between 40-80 years old
- Have a COPD diagnosis for at least 1 year
- Have had multiple flare-ups or exacerbations while on maintenance inhaler
- Are a current or former smoker
- You may have been told that you have elevated blood eosinophil (white blood cell) levels
Study Dates:
August 1, 2025 - February 28, 2028
Type of Study:
Pre-Market
Study Design:
Controlled Design
Study Location:
FL|TX
Funding Source:
GlaxoSmithKline
Contact:
Trialmed Screening Team
877-469-4154
[email protected]
ClinicalTrails.gov Identifier:
NCT06961214, NCT06959095
